SUMMER GREGSON: Open Payments
NPI 1629206321 · MCKINNEY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$521 in 21 payments from 9 companies in 2025. Trend: 2023 $456 · 2024 $462 · 2025 $521
Food & beverage: $521
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $193 |
| Astellas Pharma US Inc | 3 | $157 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| Exact Sciences Corporation | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $22 |
| Medtronic, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $16 |
Products named: Veozah, Ozempic, Wegovy, GVOKE HYPOPEN, REXULTI, Kerendia, INTELLIS ADAPTIVESTIM, SHINGRIX.
Industry payments across TX — which companies pay providers there.
